Background : In view of the changing nature of transjugular liver biopsy, we performed an audit of the safety, adequacy and clinical impact of such biopsies in our centre over a 2‐year period from 1995 to 1997. Methods : One hundred and fifty‐seven transjugular biopsies were carried out in 145 patients, with prothrombin time >5 s over control and/or platelet count <50 × 109/L and/or gross ascites. Results : Major complications were two (1.3%) capsular perforations, which were easily plugged with coils without sequelae. Biopsy sample was adequate for histological diagnosis in 90%, inadequate in 6% and technically unsuccessful in 4% of cases. Mean biopsy size was 14.8 ± 7.7 (1–51) mm. Adequacy did not differ between cases with and without cirrhosis. Transjugular biopsy had a clinical impact (specific diagnosis or influence on patient’s management) in 50% of acute liver disease, 62% of chronic liver disease and 87% of transplant patients (P < 0.001). In chronic liver disease, it had a significantly greater clinical impact in cases trying to establish the stage rather than diagnosis (84% vs. 35%, P < 0.001). Conclusions : Transjugular liver biopsy is a safe procedure for high‐risk patients providing an adequate liver sample even in cirrhosis. It has a clinical impact in more than 80% of transplant patients and for staging chronic liver disease, but in only 50% (acute) or 35% (chronic) of liver disease when a diagnosis is sought.

The mode of administering the ol. terebinlhincr in one-ounce odses, as tried by Professor Hamilton and others, is, in myopinion. an injudicious one. From one to iwo drachms of ihe rectified oil in mist, amygdal. or with an equal quantity of